PROACT LUNG Study
Lung Cancer Detection
Clinical ValidationActive
Key Facts
About Freenome
Freenome is a pioneering diagnostics company developing a multiomics and AI-powered platform for early cancer detection via blood tests. Founded in 2014 and headquartered in South San Francisco, the company's lead program is a blood-based screening test for colorectal cancer (CRC), which is undergoing validation in the large-scale PREEMPT CRC study. Freenome is also expanding its pipeline into lung cancer detection and aims to create a broad, accessible screening platform to improve cancer outcomes through earlier intervention.
View full company profileTherapeutic Areas
Other Lung Cancer Detection Drugs
| Drug | Company | Phase |
|---|---|---|
| Aeonose™ Lung Cancer Test | The eNose Company | Clinical Validation |